Investigational drug · Phase 2
REGN7075
Also called: marlotamig
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "REGN7075"
First trial start
2020
Dec 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN7075", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Advanced Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- Carcinoma Non Small Cell Lung
- Advanced Solid Tumors
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN7075" as an intervention, largest first.
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04626635 · 548 participants · Start Dec 21, 2020 · Primary completion Nov 13, 2026
Drug: REGN7075; Cemiplimab and 3 more · For: Advanced Solid Tumors
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 54 sites in all
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07154290 · 300 participants (planned) · Start Mar 18, 2026 · Primary completion Jun 10, 2030
Drug: Ubamatamab; Marlotamig and 1 more · For: Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer and 1 more
Sites: Birmingham, Alabama; Goodyear, Arizona; Irvine, California · 18 sites in all
- A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06465329 · 184 participants (planned) · Start Nov 18, 2024 · Primary completion Dec 4, 2029
Drug: Cemiplimab; Platinum-based chemotherapy and 2 more · For: Non Small Cell Lung Cancer; NSCLC
Sites: Orange, California; Skokie, Illinois; Detroit, Michigan · 47 sites in all
NSABP Foundation IncResearch network
NCT07058012 · 79 participants (planned) · Start Apr 17, 2026 · Primary completion Apr 17, 2029
Drug: Cemiplimab; cemiplimab plus fianlimab and 1 more · For: Colo-rectal Cancer
Sites: Gainesville, Florida; Iowa City, Iowa; Kansas City, Kansas · 13 sites in all
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT07281768 · 66 participants (planned) · Start Jul 14, 2026 · Primary completion Jul 2030
Drug: Oxaliplatin; Capecitabine and 3 more · For: Colorectal Cancer
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.
Saeed A, Yothers G, Puhalla SL, et al. · Future Oncol 2026
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.